Tecfidera Lymphocyte Chart Review

Completed

Conditions studied: Multiple Sclerosis

In brief

The primary objective of the study is to retrospectively investigate changes in lymphocyte counts and lymphocyte subtypes, with a focus on CD4+ and CD8+ T cells, in participants on Tecfidera therapy for at least 6 months. The secondary objective is to investigate changes in lymphocyte subtypes other than CD4+ and CD8+ T cells.

Key facts

Study ID

NCT02519413

Run by

Biogen

People needed

483

Starts

2015-07-01

Expected to finish

2016-02-01

Last updated by the study team

2016-08-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research site — Homewood, Alabama, United States
• Research Site — Newport Beach, California, United States
• Research Site — Atlanta, Georgia, United States
• Research Site — Buffalo, New York, United States
• Research Site — Patchogue, New York, United States
• Research Site — Huntersville, North Carolina, United States
• Research Site — Philadelphia, Pennsylvania, United States
• Research Site — Seattle, Washington, United States
• Research Site — Seattle, Washington, United States
• Research Site — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.